SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Trading the Trials: Cytori and Cypress Bio
FRX
|
|
|
+23.45%
in
335 days
<> 
Cytori Therapeutics (CYTX) reported preclinical study results in large animals which demonstrated the ability of adipose-derived stem and regenerative cells [ADRCs] to repair and increase the tissue density of damaged spinal discs, which was retained at both six and 12-month follow-up assessments. The study demonstrates the potential for a patient's own ADRCs to heal injured spinal discs in a safe manner (as no inflammation was present within the disc space), with results expected to be reported in full next spring.
...
|
Updated FDA Calendar of 75 Decision Dates
FRX
|
|
|
+20.32%
in
18 days
(closed on 12/09/08)
<> 
The accompanying table [click to enlarge or download] includes an updated calendar of 75 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, which includes a full slate of expected action before year-end outlined in my previous article. The last few days have been busy for antibiotics at the agency, resulting in sharply lower stock prices for Targanta Therapeutics (TARG) and Theravance (THRX).
An FDA panel voted against Targanta's oritavancin, which has an upc...
|
A Backlog of Decisions is Building at the FDA
FRX
|
|
|
-17.04%
in
14 days
(closed on 11/21/08)
<> 
The accompanying table presents 70 FDA product approval decision dates along with the market caps and one year stock price change for the underlying companies. A note of caution for investors and traders is that the most common outcome from the FDA in the past year has been a delay in decisions due to understaffed conditions at the agency. However, several companies have pending decisions which are likely to occur either before year-end or early next year and will have a major impact on their stock prices.
Disco...
|
FDA Action Heats Up Before Year-End
FRX
|
|
|
-5.04%
in
17 days
(closed on 11/07/08)
<> 
The accompanying table presents an updated calendar of expected FDA decision dates and advisory committee [FDAC] meetings expected to impact the price of underlying biotech and pharma stocks. Genzyme (GENZ) faces a FDAC tomorrow (10/21) for its pending BLA for Myozyme manufactured at the 2,000L bioreactor scale. Also, Discovery Labs (DSCO) submitted its complete response to the FDA last Friday to address an approvable ruling for Surfaxin back in May and insiders continue to buy the stock. DSCO expects the FDA to rule on Surfaxin...
|
FDA Decision Date Calendar Through January 2009
FRX
|
|
|
-15.07%
in
30 days
(closed on 10/21/08)
<> 
The accompanying table includes a calendar of expected FDA decision dates through the end of January 2009, including nine decisions due by the end of September. Some likely near-term movers on the calendar include Cypress Bioscience (CYPB) + partner Forest Labs (FRX) with a pending decision on milnacipran in the treatment of fibromyalgia slated for the end of October in addition to results from a Phase 3 trial for the drug some time before year end. Also, Discovery Labs (DSCO) is not listed on the calendar, b...
|
From the Blogosphere
Forest Laboratories: Steady Growth in Sales and Earnings
I have written about Forest Laboratories, Inc. (FRX) before. FRX is a mid-cap player in the biotech and drug markets. It is characterized by steady growth in both sales and earnings. Call this a value play. Its new product pipeline is promising, and several products are now entering Phase 3 trials.
For a detailed analysis of the company, go to https://measuredapproach.wordpress.com.
|
Notable Analyst Rating Changes 10/21: CAT, CSCO, SYK, FRX Upgraded; LMT, EAT, NVS Downgraded
UPGRADES:Goldman Sachs upgrades Caterpillar, Inc. (NYSE: CAT) from Sell to Neutral with a $64 price target.Wedbush upgrades Cisco Systems (Nasdaq: CSCO) to Outperform. Price target increased from $25 to $28. Click Here for more color.Bank of America upgrades Stryker (NYSE: SYK) from Underperform to Neutral. Cowen & Co upgrades Forest Laboratories (NYSE: FRX) from Neutral to Outperform.For daily real-time Upgrades go to http://www.streetinsider.com/UpgradesDOWNGRADES:Morgan Keegan downgrades Lockheed Martin (NYSE: LMT) from Outperform to Market Perform. Collins Stewart downgrades Lockheed ...
|
Trading Radar for 10/20: Yahoo (YHOO), Coca-Cola (KO), Caterpillar (CAT), Bank of NY Mellon (BK), Coach (COH), Lexmark (LXK) Report
The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session:<u>Before Market Opens:</u>Economics:8:30am ET- Building Permits - Street Sees 590k
- Core PPI - Street Sees 0.1%
- Housing Starts - Street Sees 610K
Earnings:Arbitron (NYSE: AIT) - consensus EPS $0.24Autolive (ALV) - consensus EPS $0.28Bank of New York Mellon (NYSE: BK) - consensus EPS $0.47Biogen Inec (NASDAQ: BIIB) - consensus EPS $1.04Blackrock (NYSE: BLK) - consensus EPS $1.90Caterpillar (NYSE: CAT) - consensus EPS $0.06Cirrus Logic (NASDAQ: CRUS) - consensus EPS $0.10Comerica (NYSE: CMA) - c...
|
Bruce Berkowitz apuesta clara por empresas sector salud
|
|
|
Dicen que Bruce Berkowitz, gestor del fondo Fairholme Fund, es lo más parecidito que hay hoy en día a Warren Buffet (si alguien puede parecerse al abuelete). Con un filosofía 100% value, pero con un toque de “timing” estratégico, las rentabilidades del Fairholme en los últimos años han sido algo más que decentes. <>Cuando me refiero a apuestas estratégicas me refiero a apuestas globales sobre el comportamiento de determinados sectores, por ejemplo Berkowitz enganchó perfectamente el ascenso de las compañías relacionadas con la energía en el boom del petróleo de los últimos 3 o 4 año<><>< /><><>< /><><><><><><><><><><><><><><><><><><><><><><><>< /><><>< /><>< /><>< /><>< /><>< />< />...
|
Spotlight on Biotech: 10 Promising Companies
The U.S. biotechnology industry includes about 1,000 companies, of all sizes, with combined annual revenues close to $50 billion. Large companies include Amgen (AMGN), Biogen Idec (BIIB), Genetic (GENE), Genzyme (GENZ), Life Technologies (LIFE) and Monsanto (MON). Because so many drugs are now developed using biotechnology, the biotech and pharmaceutical industries overlap. <>Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. With the pending introduction of Obamacare, new uncertainties are introduced to this ind...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Forest Laboratories Inc
- Answers.com
